Tearsheet

Gelteq (GELS)

Market Price (10/31/2025): $1.15 | Market Cap: $10.9 Mil
Sector: Health Care | Industry: Pharmaceuticals

Gelteq (GELS)

Market Price (10/31/2025): $1.15
Market Cap: $10.9 Mil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0			Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -3.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2300%
1			Expensive valuation multiples P/SPrice/Sales ratio is 75x
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -41%

0	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -3.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2300%
1	Expensive valuation multiples P/SPrice/Sales ratio is 75x
2	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -41%

Market Valuation & Key Metrics

Valuation
Key Metrics

	10/31/25	2024	2023	2022	2021
Share Price CYE	$1.15	$2.32
Market Cap CYE ($ Mil)	10.9	21.9	-	-	-
Total Debt ($ Mil)	3.8	3.8	2.5	1.5	0.2
Total Cash ($ Mil)	0.0	0.0	0.4	0.2	0.2
Enterprise Value ($ Mil)	14.7	25.7
Valuation Ratios
P/S TTM	73.6	0.0	0.0	0.0	0.0
P/EBIT TTM	-3.1	-7.4	0.0	0.0	0.0
P/E TTM	-2.7	-6.2	0.0	0.0	0.0
Sector Ratios
P/S TTM (Sector)	4.1	3.5	4.0	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.7
P/E TTM (Sector)	-2.0	-1.5	-1.5	-1.3	-2.8

	10/31/25	2024	2023
Share Price CYE	$1.15	$2.32
Market Cap CYE ($ Mil)	10.9	21.9	-
Total Debt ($ Mil)	3.8	3.8	2.5
Total Cash ($ Mil)	0.0	0.0	0.4
Enterprise Value ($ Mil)	14.7	25.7
Valuation Ratios
P/S TTM	73.6	0.0	0.0
P/EBIT TTM	-3.1	-7.4	0.0
P/E TTM	-2.7	-6.2	0.0
Sector Ratios
P/S TTM (Sector)	4.1	3.5	4.0
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4
P/E TTM (Sector)	-2.0	-1.5	-1.5

	GELS	S&P 500
REVENUE GROWTH	FAIR
Rev LTM ($ Bil)	0.0
Rev Chg Q	�	6.4%
Rev Chg LTM	�	5.4%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	�
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-2,299.9%	18.7%
Net Inc Mgn	-2,741.7%	12.8%
VALUATION	VERY HIGH
P/S	73.6	3.2
P/E	-2.7	23.6
STABILITY	POOR
Debt/Equity	0.35	0.21
Cash/Assets	0.00	0.07

GELS Stock

Return (1M):

Factor Drivers of Stock Movement

The -32.4% change in GELS stock from 7/31/2025 to 10/30/2025 was primarily driven by a -32.4% change in the company's P/S Multiple.

	7312025	10302025	Change
Stock Price ($)	1.73	1.17	-32.37%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.15	0.15	0.00%
P/S Multiple	110.67	74.85	-32.37%
Shares Outstanding (Mil)	9.44	9.44	0.00%
Cumulative Contribution			-32.37%

LTM = Last Twelve Months as of date shown

The -37.1% change in GELS stock from 5/1/2025 to 10/30/2025 was primarily driven by a -37.1% change in the company's P/S Multiple.

	5012025	10302025	Change
Stock Price ($)	1.86	1.17	-37.10%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.15	0.15	0.00%
P/S Multiple	118.99	74.85	-37.10%
Shares Outstanding (Mil)	9.44	9.44	0.00%
Cumulative Contribution			-37.10%

LTM = Last Twelve Months as of date shown

The -50.6% change in GELS stock from 10/30/2024 to 10/30/2025 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).

	10302024	10302025	Change
Stock Price ($)	2.37	1.17	-50.62%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	�	0.15	�
P/S Multiple	�	74.85	�
Shares Outstanding (Mil)	9.44	9.44	0.00%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

null

null

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
GELS Return	-	-	-	-	-	-50%	-47%
Peers Return	-10%	-6%	-26%	-27%	-27%	2488%	759%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	110%
Monthly Win Rates [3]
GELS Win Rate	-	-	-	-	50%	33%
Peers Win Rate	22%	30%	22%	23%	32%	44%
S&P 500 Win Rate	58%	75%	42%	67%	75%	67%
Max Drawdowns [4]
GELS Max Drawdown	-	-	-	-	-	-65%
Peers Max Drawdown	-17%	-13%	-31%	-34%	-35%	-27%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: BGM, NSRX, RGC, RHHBY, SXTC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

GELS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique Key	Event	XLV	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-16.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	19.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	599 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-28.8%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	40.4%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	116 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-15.8%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	18.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	326 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-40.6%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	68.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1100 days	1480 days

Compare to

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Gelteq (GELS)

Business Description

We are a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. A “white label” gel-based delivery solution is where we produce a product that other companies rebrand as their own product. Our principal products are edible gels, which we refer to as gels, and their application in gel-based dosage forms. Our current product suite consists of multiple products that sit within five core verticals — for pets, sports, pharmaceutical (pharma), over-the-counter (OTC) and nutraceutical — all of which leverage our patent pending multiple-ingredient dosage forms, and that we expect to have a wide range of applications and consumers. We currently focus our efforts on out-licensing our technology to companies to develop and create new products they can manufacture and sell within their established and researched markets, while we continue to manufacture our existing products under license (“white label”). Of our products already licensed, two clients have placed initial orders for nutraceutical products, and there have been four other products in the sports vertical ordered. From these orders, we shipped 15,000 units during May 2022, 250,000 units during June 2022 and 60,000 units in December 2022. For the year ended June 30, 2023, the 60,000 units delivered in December 2022 has been recognized as revenue of AUD$79,843 (USD$57,487) from the deferred revenue balance at June 30, 2022. The Company expects to fulfill the remaining orders in the fiscal year ending June 30, 2025. In January 2023, one of our existing clients placed further orders for two new products totaling 120,000 units, of which we received a AUD$45,437 (USD$32,715) non-refundable deposit for such orders in May 2023, and a new client placed an order for 80,000 units. As of August 2024, the delay on outstanding deliveries is due to certain of our clients experiencing cash flow difficulties and currently being unable to pay for their outstanding orders. These customers have not cancelled their orders and they expect to resolve their cash flow difficulties and we plan to manufacture and deliver such units ordered as soon as they resolve their cash flow difficulties in the fiscal year ending June 30, 2025. In October 2023, we received a further order for 200,000 units in our nutraceutical vertical, of which we received a non-refundable deposit of AUD$40,000 (USD$28,800). The October 2023 order was requested by the customer to be manufactured in the fourth quarter in the calendar year 2024, and as such we expect to manufacture and deliver the October 2023 orders in the fiscal year ending June 30, 2025. We have also put in place greater rigorous qualification procedures to ensure future customers have the financial ability to fund orders through to manufacturing in a timely manner. Also, due to world-wide supply chain delays which affected timing of prior product shipments, we have also put in place strategies to mitigate delays in the future, including establishing an additional sampling and research and development facility at its headquarters in Melbourne, Australia. The Company expects to finalize a dedicated production line with a GMP certified manufacturer in Melbourne, Australia in the fiscal year ending June 30, 2025 to further enhance production capacity which will avoid future delays. For the year ended June 30, 2022, we invoiced a total of AUD$267,301 (USD$192,457) for units ordered, of which approximately AUD$147,536 (USD$106,226) was delivered to customers and recognized as revenue. The remaining AUD$119,765 (USD$86,231) was for orders that have been invoiced but not delivered and as such were not recognized as revenue and are considered deferred revenue. As a result, for the year ended June 30, 2022, approximately 50.2% of the orders ordered were with related parties and 91% of revenue recognized were with related parties. For the year ended June 30, 2023 and for the nine months ended March 31, 2024, total units ordered were 200,000 for both periods and none were with related parties. Cumulatively, from our inception through March 31, 2024, approximately 23% of total units ordered were from related parties and none of the January 2023 or October 2023 orders were from related parties. With regards to the pets, nutraceutical and sports vertical, we designed these products to have no regulatory hurdles to overcome as they have food grade classifications and therefore do not require regulatory approvals. We designed our gel platform to enhance the tolerability and stability of drugs while maintaining their efficacy. Products in the pharma vertical will require regulatory approval. We have been funded since inception through a combination of equity contributions, related party loans and Australian government grants/tax incentives. We will continue to balance our research and development alongside our revenue generating activities, with AUD$ Nil of recognized revenue plus deferred revenue of AUD$40,000 (US$28,800) received for the nine months ended March 31, 2024, resulting in an aggregate deferred revenue of AUD$125,359 (US$90,258) as at March 31, 2024. For the financial year ended June 30, 2023, we generated AUD$79,843 (USD$57,487) of recognized revenue which are attributable to deferred revenue, plus deferred revenue of AUD$45,437 (USD$32,714) received in the financial year ended June 30, 2023 resulting in an aggregate deferred revenue of AUD$85,359 (USD$61,458) as at June 30, 2023. For the financial year ended June 30, 2022, we generated AUD$147,536 (USD$106,226) of recognized revenue attributable to deferred revenue and AUD$267,301 (USD$192,457) of deferred revenue received in the financial year ended June 30, 2022, resulting in an aggregate deferred revenue of AUD$119,765 (USD$86,231) as at June 30, 2022. We have prepared and applied for patents which relate to a diagnostic gel product comprising glucose, and certain multiple-health ingredient dosage forms. Our first patent family is comprised of the granted U.S. patent 10,983,132, the People’s Republic of China patent CN108289963B and Australia patent 2016351301 which is for an oral glucose tolerance test gel and testing method for diabetes diagnostics, and pending patent applications in the following additional countries or jurisdictions: Canada, the European Patent Office, India and Qatar. We are seeking to protect products that employ our gel technology in our second patent family which is directed to certain multiple-health ingredient dosage forms which utilize a gel formulation that features agarose and alginate that in certain ratios and pH ranges form gels of specific firmness to deliver two or more health ingredients (including medicines) in a single dosage form. This second patent family is comprised of the granted European Patent Office patent 3809877 and patent pending applications in the following countries: Australia, Brazil, Canada, the Eurasian Patent Organization, Israel, India, Japan, South Korea, Mexico, the People’s Republic of China, Saudi Arabia, the United Arab Emirates, the United States, and South Africa. Our vision is to change the way good health is delivered to both humans and animals through our patent pending multiple-health-ingredient gel dosage forms. We have pending trademark registrations for “Gelteq” in Australia, the United States and several other countries and jurisdictions and registered trademarks for “Gelteq” in Japan, the People’s Republic of China, South Korea, Thailand, the United Kingdom and several other countries and jurisdictions. We also have a registered trademark for the Gelteq logo and “Pet Gels” logo in the United Kingdom, which we expect will both be submitted for approval as registered trademarks in the countries and jurisdictions where we have pending and registered trademarks for “Gelteq” referred to in the immediately preceding sentence. We also have pending trademark registrations for a stylized logo of “SportsGel” in Australia, the United States and several other countries and jurisdictions. We continue to work on preparing additional patent applications. Our third patent application addresses challenges with delivering oil-based products in gels, our fourth patent application covers products produced for the nutritional health dysphagia market where swallowing tablets is challenging, and our fifth patent application addresses pharmaceutical formulations with the delivery of a single Active Pharmaceutical Ingredient (API). These applications have been lodged as provisional patents in the United Kingdom in August 2022, December 2022 and May 2023, respectively. We expect to file our sixth and seventh patent families in the first quarter of the fiscal year ending June 30, 2025 to further protect the varying APIs that our gel delivery platform can hold. We anticipate to lodge additional patent applications in addition to our sixth and seventh patent families during the financial year ending June 30, 2025, as we further increase our intellectual property portfolio as we continue to attain U.S. Food and Drug Administration (FDA) approvals for our gel-based drug dosage forms through the 505(b)(2) pathway. We will continue to seek to protect our intellectual property through a combination of patents, trademarks, trade secrets, non-disclosure and confidentiality agreements, assignments of invention and other contractual arrangements with our employees, consultants, partners, manufacturers, customers and others. We believe these efforts have the potential to protect various proprietary applications of our gel delivery system from imitation. We were incorporated under the laws of the State of Victoria, Australia on October 15th, 2018. Our technology was assigned to us by our founders and a predecessor entity, who created it prior to the incorporation of our company. The intellectual property was then assigned to Gelteq at Gelteq’s inception to continue to build on this work. We currently have two direct, wholly-owned subsidiaries as part of our organizational structure: Nutrigel Pty Ltd and Unit Trust (“NPL”) and Sport Supplements Pty Ltd and Unit Trust (“SSPL”). Our registered office is located at Vistra Australia, Level 4, 100 Albert Road, South Melbourne VIC, 3025, Australia. Our principal place of business is located at 639-641 Glenhuntly Road, Caulfield, VIC 3162, Australia.

Better Bets than Gelteq (GELS)

	GELS	Better Performance than GELS
Metric	Value	Industry (Pharmaceuticals)
Op Mgn LTM	-2299.9%	LLY (43.0%), JNJ (26.2%), MRK (31.2%), PFE (26.1%), BMY (23.8%)
Total Yield	-36.6%	LLY (2.5%), JNJ (8.2%), MRK (11.3%), PFE (13.0%), BMY (11.9%)

	GELS	Better Performance than GELS
Metric	Value	Sector (Health Care)
Op Mgn LTM	-2299.9%	LLY (43.0%), JNJ (26.2%), ABBV (23.5%), UNH (6.1%), ABT (17.6%)
Total Yield	-36.6%	LLY (2.5%), JNJ (8.2%), ABBV (3.7%), UNH (8.1%), ABT (8.3%)

	GELS	Better Performance than GELS
Metric	Value	All Other Sectors
Op Mgn LTM	-2299.9%	NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AMZN (11.4%)
Total Yield	-36.6%	NVDA (1.8%), AAPL (2.8%), MSFT (3.3%), GOOGL (3.9%), AMZN (3.0%)

		Best Bets In Health Care Sector
	GELS	RPRX	HALO	CPRX	BMY	LNTH	PBH	BIIB	PFE	EW	ILMN
What You Pay
P/E	-2.7	15.3	14.1	12.3	15.4	14.0	14.0	13.6	12.8	11.8	12.4
P/EBIT	-3.1	8.1	11.0	10.5	9.3	9.6	9.0	10.1	10.3	29.2	10.3
What You Get
Rev Chg Q	�	7.7%	40.8%	19.4%	2.8%	-4.1%	-6.6%	2.8%	10.3%	11.9%	-4.8%
Rev Chg LTM	�	3.0%	35.0%	28.5%	1.3%	5.7%	0.6%	4.8%	13.5%	9.1%	-3.3%
Rev Chg 3Y Avg	�	0.8%	35.5%	49.9%	1.0%	34.3%	0.8%	-0.9%	-12.4%	3.0%	-3.0%
FCF/Rev 3Y Avg	�	113.4%	43.4%	38.9%	29.0%	26.1%	21.6%	17.0%	13.8%	11.9%	9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Gelteq Stock Dropped 17% - Have You Assessed the Risk	Return

	Title
0	ARTICLES
1	Gelteq Stock Dropped 17% - Have You Assessed the Risk

Trade Ideas

Select past ideas related to GELS. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	5.9%	5.9%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.1%	16.1%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.6%	2.6%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.2%	14.2%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	15.2%	15.2%	-8.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	5.9%	5.9%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.1%	16.1%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.6%	2.6%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.2%	14.2%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	15.2%	15.2%	-8.0%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PRAX	Praxis Precision Medicines	279.1%	161.2%
2	INBX	Inhibrx Biosciences	131.0%	409.8%
3	PUMP	ProPetro	99.6%	16.2%
4	DYN	Dyne Therapeutics	88.4%	-0.0%
5	VICR	Vicor	85.4%	89.2%
6	CELC	Celcuity	74.6%	503.2%
7	GLUE	Monte Rosa Therapeutics	73.5%	87.5%
8	NVTS	Navitas Semiconductor	72.1%	251.8%
9	LUMN	Lumen Technologies	70.3%	94.7%
10	BALY	Ballys	63.4%	4.1%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	-62.9%	5106.3%
2	LRN	Stride	-53.8%	-35.8%
3	FMC	FMC	-51.0%	-66.6%
4	FI	Fiserv	-48.3%	-68.3%
5	NFE	New Fortress Energy	-43.6%	-91.9%
6	VG	Venture Global	-41.7%
7	OGN	Organon	-40.2%	-55.0%
8	VRNS	Varonis Systems	-39.5%	-21.2%
9	ITGR	Integer	-38.5%	-52.2%
10	LENZ	LENZ Therapeutics	-37.9%	5.5%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

Peer Comparisons for Gelteq

Financials

	GELS	BGM	NSRX	RGC	RHHBY	SXTC	Median
Name	Gelteq	BGM	Nasus Ph.	Regencel.	Roche	China SX.
Mkt Price	1.17	9.12	7.78	16.35	40.56	1.36	8.45
Mkt Cap	0.0	-	-	-	-	-	0.0
Rev LTM	0	-	-	-	-	-	0
Op Inc LTM	-3	-	-	-	-	-	-3
FCF LTM	-	-	-	-	-	-	-
FCF 3Y Avg	-	-	-	-	-	-	-
CFO LTM	-	-	-	-	-	-	-
CFO 3Y Avg	-	-	-	-	-	-	-

Growth & Margins

	GELS	BGM	NSRX	RGC	RHHBY	SXTC	Median
Name	Gelteq	BGM	Nasus Ph.	Regencel.	Roche	China SX.
Rev Chg LTM	-	-	-	-	-	-	-
Rev Chg 3Y Avg	-	-	-	-	-	-	-
Rev Chg Q	-	-	-	-	-	-	-
QoQ Delta Rev Chg LTM	0.0%	-	-	-	-	-	0.0%
Op Mgn LTM	-2,299.9%	-	-	-	-	-	-2,299.9%
Op Mgn 3Y Avg	-	-	-	-	-	-	-
QoQ Delta Op Mgn LTM	-381.6%	-	-	-	-	-	-381.6%
CFO/Rev LTM	-	-	-	-	-	-	-
CFO/Rev 3Y Avg	-	-	-	-	-	-	-
FCF/Rev LTM	-	-	-	-	-	-	-
FCF/Rev 3Y Avg	-	-	-	-	-	-	-

Valuation

	GELS	BGM	NSRX	RGC	RHHBY	SXTC	Median
Name	Gelteq	BGM	Nasus Ph.	Regencel.	Roche	China SX.
Mkt Cap	0.0	-	-	-	-	-	0.0
P/S	74.8	-	-	-	-	-	74.8
P/EBIT	-3.1	-	-	-	-	-	-3.1
P/E	-2.7	-	-	-	-	-	-2.7
P/CFO	-	-	-	-	-	-	-
Total Yield	-36.6%	-	-	-	-	-	-36.6%
Dividend Yield	0.0%	-	-	-	-	-	0.0%
FCF Yield 3Y Avg	-	-	-	-	-	-	-
D/E	0.3	-	-	-	-	-	0.3
Net D/E	0.3	-	-	-	-	-	0.3

Returns

	GELS	BGM	NSRX	RGC	RHHBY	SXTC	Median
Name	Gelteq	BGM	Nasus Ph.	Regencel.	Roche	China SX.
1M Rtn	-15.2%	-10.9%	17.0%	5.8%	-3.0%	-13.4%	-7.0%
3M Rtn	-32.4%	7.8%	-	23.9%	4.2%	-12.8%	4.2%
6M Rtn	-37.1%	-19.3%	-	706.9%	2.5%	-38.7%	-19.3%
12M Rtn	-50.6%	23.1%	-	8,893.4%	6.2%	-70.6%	6.2%
3Y Rtn	-	-	-	2,156.1%	14.1%	-98.9%	14.1%
1M Excs Rtn	-11.0%	-12.2%	28.0%	1.6%	-11.2%	-16.7%	-11.1%
3M Excs Rtn	-37.1%	-3.3%	-	16.7%	-4.9%	-29.4%	-4.9%
6M Excs Rtn	-58.8%	-41.0%	-	685.2%	-19.3%	-60.5%	-41.0%
12M Excs Rtn	-	-0.8%	-	10,069.8%	-13.2%	-88.3%	-7.0%
3Y Excs Rtn	-	-	-	2,079.3%	-63.7%	-175.7%	-63.7%

Financials

Annual
Quarterly

$ Mil \| FY: 6/30	LTM	2024	2023	2022	2021	2020
Period End	6/30/2024	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020
Filing Date	11/15/2024	11/15/2024	10/22/2024	12/9/2022	12/9/2022	12/9/2022
Key Financials
Total Revenue	0	0	0	0	0	0
EBITDA	-2	-2	-2	-2	-1	-1
Operating Income	-3	-3	-3	-3	-1	-1
Net Income	-4	-4	-4	-3	-1	-0
EPS	-0.43	-0.38	-0.37	-0.36	-0.07	-0.16
Growth Rates
Total Revenue Growth	-	-100.0%	-45.9%	∞%	-	-
EBITDA Growth	-	6.8%	5.2%	-235.6%	-11.8%	-
Operating Income Growth	-	17.9%	-5.8%	-393.2%	-22.3%	-
Net Income Growth	-	-1.1%	-4.1%	-419.2%	-72.8%	-
Margins
EBITDA Margin	-1570.7%	-	-2349.9%	-1341.5%	-	-
Operating Income Margin	-2299.9%	-	-4232.9%	-2165.1%	-	-
Net Income Margin	-2741.7%	-	-4391.4%	-2283.4%	-	-
Cash & Debt
Total Cash	0	0	0	0	0	0
Total Debt	4	4	2	2	0	0
Net Debt / (Cash)	4	4	2	1	-0	-0
Cash Flows
Net Cash from Operations	-	�	�	�	�	�
Free Cash from Operations	-	�	�	�	�	�
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 6/30	2024Q4	2024Q3	2023Q4	2022Q4	2021Q4
Period End	6/30/2024	3/31/2024	6/30/2023	6/30/2022	6/30/2021
Filing Date	11/15/2024	10/22/2024	10/22/2024	12/9/2022	12/9/2022
Key Financials Quarterly
Total Revenue	0	0	0	0	0
Ebitda	-1	-0	-1	-1	-0
Operating Income	-1	-1	-1	-1	-0
Net Income	-1	-1	-1	-1	-0
EPS	-0.12	-0.08	-0.10	-0.13	-0.02
Key Financials TTM
Total Revenue TTM	0	0	-	-	-
Ebitda TTM	-2	-2	-	-	-
Operating Income TTM	-3	-3	-	-	-
Net Income TTM	-4	-3	-	-	-
Growth Rates Quarterly
Total Revenue Growth	-	-	-	-	-
EBITDA Growth	-286.4%	-	-	-	-
Operating Income Growth	-242.5%	-	-	-	-
Net Income Growth	-385.5%	-	-	-	-
Margins Quarterly
EBITDA Margin	-	-	-	-562.7%	-
Operating Income Margin	-	-	-	-768.0%	-
Net Income Margin	-	-	-	-838.2%	-
Cash & Debt
Total Cash	0	0	0	0	0
Total Debt	4	3	2	2	0
Net Debt / (Cash)	4	3	2	1	-0
Cash Flows Quarterly
FCF from Operations	-	-	-	-	-
Cash Flows TTM
FCF from Operations TTM	-	-	-	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-10.5%	-7.7%	-12.4%	-17.0%	-3.7%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-11.2%	-9.5%	-	-	-

Price Behavior

Price Behavior

Market Price	$1.17
Market Cap ($ Bil)	0.0
First Trading Date	10/29/2024
Distance from 52W High	-75.6%
	50 Days	200 Days
DMA Price	$2.91	$2.94
DMA Trend	down	down
Distance from DMA	-59.7%	-60.1%
	3M	1YR
Volatility	157.2%	312.9%
Downside Capture	-97.66	207.37
Upside Capture	-249.22	104.26
Correlation (SPY)	3.2%	13.3%

GELS Betas & Captures as of 9/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	-9.27	-0.81	-0.33	2.46	-0.09	-0.56
Up Beta	4.93	3.79	1.32	2.99	4.58	-3.01
Down Beta	21.76	7.70	6.82	0.86	2.38	0.82
Up Capture	-626%	-292%	-184%	309%	118%	11%
Bmk +ve Days	13	23	35	74	144	420
Stock +ve Days	9	16	24	48	92	92
Down Capture	-2958%	-454%	-244%	185%	149%	94%
Bmk -ve Days	8	19	29	52	107	330
Stock -ve Days	10	23	36	72	127	127

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	11,234
Short Interest: % Change Since 9302025	-72.2%
Average Daily Volume	256,856
Days-to-Cover Short Interest	1
Basic Shares Quantity	9,438,075
Short % of Basic Shares	0.1%

Returns Analyses

	Title
0	Gelteq Stock Dropped 17% - Have You Assessed the Risk

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12312024	6302025	6-K 12/31/2024
6302024	11152024	20-F 6/30/2024
6302023	10222024	424B4 6/30/2023
3312023	8032023	F-1/A 3/31/2023
6302022	12092022	F-1/A 6/30/2022
3312022	8302022	F-1 3/31/2022

Insider Activity

Expand for More

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Gelteq (GELS)

Market Price (10/31/2025): $1.15 | Market Cap: $10.9 MilSector: Health Care | Industry: Pharmaceuticals

Gelteq (GELS)

Market Price (10/31/2025): $1.15Market Cap: $10.9 MilSector: Health CareIndustry: Pharmaceuticals

Market Valuation & Key Metrics

GELS Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Gelteq (GELS)

Interactive Breakdown

Better Bets than Gelteq (GELS)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Gelteq

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (10/31/2025): $1.15 | Market Cap: $10.9 Mil
Sector: Health Care | Industry: Pharmaceuticals

Market Price (10/31/2025): $1.15
Market Cap: $10.9 Mil
Sector: Health Care
Industry: Pharmaceuticals